secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2026-05-28T13:11:20+00:00
Accession:  0001493152-26-025554
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic and Scripps Research collaborate on hantavirus antibody and vaccine development using C1 platform
--------------------------------------------------------------------------------

- Collaboration to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus causing Hantavirus Pulmonary Syndrome.
- Builds on prior Andes virus monoclonal antibody work; C1 platform aims for rapid, scalable biologic production.
- C1 platform previously applied to RSV, malaria, Andes, Ebola, Marburg; demonstrated comparable neutralization to mammalian systems.
- Dyadic currently in funded collaborations with Gates Foundation, CEPI, and FBS for accelerating vaccine/antibody development.
- Parties plan to explore external partnership and non-dilutive funding opportunities to support further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226025554/0001493152-26-025554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226025554/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-025554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer